Pharmaceutical

China NMPA approves KeChow’s tunlametinib for melanoma

The China NMPA has granted approval to KeChow Pharma's tunlametinib for treating patients with NRAS-mutated advanced melanoma.

Mar 20, 2024 - 00:00
China NMPA approves KeChow’s tunlametinib for melanoma
The China NMPA has granted approval to KeChow Pharma's tunlametinib for treating patients with NRAS-mutated advanced melanoma.
Read the original article

Tags:

Previous Article

AstraZeneca to acquire radioconjugate biotech Fusion in $2.4bn deal

Next Article

Microsoft and NVIDIA expand collaboration in healthcare innovation

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Sotigalimab by Pyxis Oncology for Esophageal Cancer: Li...

Oct 27, 2023

STAT+: Like a vampire, some cancer cells can suck the energy source from immune cells

STAT+: Like a vampire, some cancer cells can suck the e...

Oct 14, 2023

Ultra-processed food is causing a boom for obesity drug Ozempic

Ultra-processed food is causing a boom for obesity drug...

Nov 9, 2024